SEATTLE, Wa., August 19, 2015 – Adaptive Biotechnologies, the leader in next generation sequencing (NGS) to profile T- and B-cell receptors of the adaptive immune system, announces a publication in Science Translational Medicine on a novel first-in-class technology for pairing T-cell receptor (TCR) alpha and beta chain sequences at high throughput. The pairSEQ™ Assay employs a pioneering proprietary process that combines Adaptive’s foundational immunoSEQ® Platform for sequencing each TCR chain independently with a sophisticated bioinformatics framework to facilitate pairing of these chains. The pairSEQ Assay enables highly accurate, rapid and scalable pairing of up to hundreds of thousands of TCR alpha or beta sequences in a single experiment and can be applied to the process of therapeutic discovery, including the identification of highly promising TCRs for adoptive T-cell therapy.
“The amount of data that the pairSEQ Assay provides can be used to investigate the connection between the primary sequence of adaptive immune receptors and their associated antigenic targets,” said Harlan Robins, PhD, Computational Biology Program Head at the Fred Hutchinson Cancer Research Center and Chief Scientific Officer and Co-Founder at Adaptive Biotechnologies. “The result is a starting point from which the efficacy and safety of a TCR therapeutic candidate can be evaluated across multiple applications at significantly expedited speed.”
Adaptive scientists, in partnership with scientists from the Fred Hutchinson Cancer Research Center, have discovered how to pair the chains together from both blood and solid tissue using the pairSEQ Assay. In a series of experiments over 350,000 paired receptor sequences were identified, and the accuracy of the method was demonstrated by showing excellent quantitative control of false discovery rate (≤1%) in a mixed-sample validation experiment.
The accurate identification of alpha and beta chain pairs, which has tremendous application in ascribing TCR functionality, has been a longstanding challenge in immunology because the two chains appear on different chromosomes in a cell. The pairSEQ Assay enables input of multiple sample types and preparations, addressing the challenges and circumventing the need for single cell technologies. The pairSEQ Assay lays the foundation for Adaptive Therapeutics, a new business area for the Company that will focus on revolutionizing TCR therapeutic discovery in immune-mediated diseases, like cancer. Adaptive is also developing the pairSEQ technology for B-cell sequencing.
“Our intent is to deploy significant capital from our recent Series F financing to hire a world-class team to integrate this ground-breaking technology into drug development efforts focused on leveraging the immune system to treat many diseases, starting with cancer,” said Chad Robins, President, CEO and Co-Founder of Adaptive Biotechnologies. “We believe that over time our discovery platform will enable our partners and our own therapeutics team to deliver highly targeted TCRs for T-cell therapeutics.”
Adaptive helps researchers make discoveries in oncology, autoimmune disorders and infectious diseases by offering fee-for-service access to its proprietary immune profiling sequencing technology under the immunoSEQ brand name. The immunoSEQ Kit is now available for research use only to facilitate the integration of immunosequencing into research centers. The immunoSEQ Assay is not for use in diagnostic procedures.
About Adaptive Biotechnologies®
Adaptive Biotechnologies is the pioneer and leader in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive is bringing the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care. For more information please visit www.adaptivebiotech.com.